Figure 2.

Factor B ASO effectively reduces plasma and ocular factor B protein levels. C57BL/6J mice were treated for 6 weeks with the indicated weekly doses of the factor B antisense oligonucleotide (ASO) via subcutaneous injection (n = 4 per group). A: Dose-dependent reduction in plasma factor B protein levels after administration of the factor B ASO. One microliter of plasma from all individual mice from the various treatment groups was analyzed with western blot. B: Dose-dependent reduction in ocular factor B protein with the administration of the factor B ASO. One whole eye from each mouse was used for total protein isolation. The factor B protein level was measured with western blot with the anti-factor B antibody.